Related Experiment Video
Updated: May 14, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
Amiodarone-induced pulmonary toxicity--a fatal case report and literature review
Felix T Range1, Ekkehard Hilker, Günter Breithardt
1Department of Cardiology and Angiology, University Hospital of Muenster, Münster, Germany. ftrange@yahoo.de
Abstract:
Amiodarone is a widely used and very potent antiarrhythmic substance. Among its adverse effects, pulmonary toxicity is the most dangerous without a causal treatment option. Due to a very long half-life, accumulation can only be prevented by strict adherence to certain dosage patterns. In this review, we outline different safe and proven dosing schemes of amiodarone and compare the incidence and description of pulmonary toxicity. Reason for this is a case of fatal pulmonary toxicity due to a subacute iatrogenic overdosing of amiodarone in a 74-year-old male patient with known severe coronary artery disease, congestive heart failure and ectopic atrial tachycardia with reduced function of kidneys and liver but without preexisting lung disease. Within 30 days, the patient received 32.2 g of amiodarone instead of 15.6 g as planned. Despite early corticosteroid treatment after fast exclusion of all other differential diagnoses, the patient died another month later in our intensive care unit from respiratory failure due to bipulmonal pneumonitis.
Related Concept Videos
Drug Toxicity: Risk factors
Drug Toxicity: Overview
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Coronary Artery Disease III: Clinical Manifestations
Heart Failure Drugs: Inotropic Agents
Drug Toxicity: Dose-Dependent Reactions